From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential to become new treatments.

In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial ...

SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, today announced a $100 million Series C ...

CareDx, Inc. - The Transplant Companytm ? a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has ...

A research team led by Professor Hwang Ho-sik of the Catholic University of Korea's Yeouido St. Mary's Eye Hospital has ...

The following is a summary of “Outcomes of staged conjunctival flap and corneal transplantation for infectious keratitis ...

Future Market Insights (FMI) has unveiled a compelling new report forecasting significant expansion in the global fuchs ...

The corneal transplant market was projected to attain US$ 444.3 million in 2023. It is likely to garner a 5.6% CAGR from 2024 ...

Dr. Ana Cornea, MD works in Chattanooga, TN as a Diabetes & Metabolism Endocrinologist. Dr. Cornea is board certified in Diabetes, Metabolism & Endocrinology. Dr. Cornea completed a residency at ...

Furthermore, artificial cornea is an option for transplant patients who cannot tolerate a human donor cornea. The global artificial cornea and corneal implant market is expected to witness a ...